<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139725">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02113982</url>
  </required_header>
  <id_info>
    <org_study_id>STML-401-0114</org_study_id>
    <nct_id>NCT02113982</nct_id>
  </id_info>
  <brief_title>SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stemline Therapeutics, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stemline Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, open-label, multi center study.  A cycle of therapy is 5
      consecutive days every 21 days for 6 or more cycles.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Primary Outcome Measures include Safety and Efficacy</measure>
    <time_frame>Please refer to the Study Completion date</time_frame>
  </primary_outcome>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>SL-401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SL-401</intervention_name>
    <arm_group_label>SL-401</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion / Exclusion Criteria to be provided
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Rowinsky, MD</last_name>
    <phone>646-203-2311</phone>
    <email>erowinsky@stemline.com</email>
  </overall_contact>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>March 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
